Immunomodulatory compounds and methods of use thereof

Details Immunomodulatory compounds and methods of use thereof Immunomodulatory compounds and methods of use thereof

2011-03-29

2011-03-29

Olson, Eric S (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C514S104000, C514S114000, C514S119000, C514S121000, C514S642000, C558S159000, C558S160000

Reexamination Certificate

active

07915238

ABSTRACT:
The present invention is directed to methods of treating diseases and disorders related to immune responses by administering one or more immunomodulatory compounds. In particular, the invention is directed to methods of stimulating and reducing immune responses, therapeutic and prophylactic treatment of cancer, treating autoimmune conditions, treating allergic reactions and asthma, and preventing ischemic damage and asthma by administering one or more immunomodulatory compounds.

REFERENCES:
patent: 5484911 (1996-01-01), Hong et al.
patent: 5635188 (1997-06-01), Bystryn
patent: 5681824 (1997-10-01), Christ et al.
patent: 5895653 (1999-04-01), Eibl et al.
patent: 5904925 (1999-05-01), Exner
patent: 5961970 (1999-10-01), Lowell et al.
patent: 5985284 (1999-11-01), Lowell
patent: 6136797 (2000-10-01), Zilch et al.
patent: 6146632 (2000-11-01), Momin et al.
patent: 6146659 (2000-11-01), Rahman
patent: 6165502 (2000-12-01), Oleske et al.
patent: 6172049 (2001-01-01), Dwyer et al.
patent: 6180111 (2001-01-01), Stein et al.
patent: 6284267 (2001-09-01), Aneja
patent: 6290973 (2001-09-01), Hawkins et al.
patent: 6306404 (2001-10-01), LaPosta et al.
patent: 6355257 (2002-03-01), Johnson et al.
patent: 6437165 (2002-08-01), Mandala et al.
patent: 6461637 (2002-10-01), Rahman
patent: 6521776 (2003-02-01), Hawkins et al.
patent: 6551600 (2003-04-01), Hawkins et al.
patent: 6630161 (2003-10-01), Leesman
patent: 6835721 (2004-12-01), Hawkins et al.
patent: 7416726 (2008-08-01), Ravetch
patent: 7560584 (2009-07-01), Hawkins et al.
patent: 7683200 (2010-03-01), Fang et al.
patent: 2002/0049314 (2002-04-01), Hawkins et al.
patent: 2002/0176861 (2002-11-01), Hawkins et al.
patent: 2003/0153532 (2003-08-01), Hawkins et al.
patent: 2004/0006242 (2004-01-01), Hawkins et al.
patent: 2005/0123566 (2005-06-01), Hawkins et al.
patent: 2005/0164988 (2005-07-01), Hawkins et al.
patent: 2007/0020232 (2007-01-01), Rossignol et al.
patent: 2007/0027111 (2007-02-01), Hawkins et al.
patent: 2007/0292418 (2007-12-01), Fields et al.
patent: 0 390 216 (1990-03-01), None
patent: 02-261866 (1990-10-01), None
patent: WO 93/04672 (1993-03-01), None
patent: WO 95/11700 (1995-05-01), None
patent: WO 98/57659 (1998-12-01), None
patent: WO 00/44758 (2000-08-01), None
patent: WO 00/73263 (2000-12-01), None
patent: WO 01/46127 (2001-06-01), None
patent: WO 01/90129 (2001-11-01), None
patent: WO 02/09752 (2002-02-01), None
patent: WO03/003985 (2003-01-01), None
patent: WO 03/011223 (2003-02-01), None
Gokhale et al., “An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological, and therapeutic evaluation” British Journal of Cancer (1996) vol. 74, pp. 43-48.
The Merck Manual of Diagnosis and Therapy, seventeenth edition, 1999, Published by Merck Research Laboratories, pp. 397-398, 948-949, 1916, and 1979-1981.
The Oxford Textbook of Oncology, 1995, published by Oxford University Press, pp. 447-453.
Merriam-Webster's Collegiate Dictionary, Tenth Edition, published 1998 by Merriam-Webster, Incorporated, p. 924.
Przetak et al., “Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice” Vaccine (2003) vol. 21 pp. 961-970.
Braga et al., “Making crystals from crystals: a green route tocrystal engineering and polymorphism” Chemical Communications (2005) pp. 3635-3645.
Jain et al., “Polymorphism in Pharmacy” Indian Drugs (1986) vol. 23, No. 6, pp. 315-329.
Vippagunta et al., “Crystalline Solids” Advanced Drug Delivery Reviews (2001) vol. 48 pp. 3-26.
Pharmaceutical Dosage Forms: Tablets, vol. 2, Published 1990 by Marcel Dekker, Inc., ed. By Lieberman, Lachman, and Schwartz, pp. 462-472.
Berzoksky and Berkower, “Chapter 8: Immunogenicity and Antigen Structure,”Fundamental Immunology, William E. Paul, ed., Raven Press NY, p. 242 (1993).
Bhattacharya et al., “Synthesis and Vesicle Formation from Novel Pseudoglyceryl Dimeric Lipids. Evidence of Formation of Widely Different Membrane Organizations with Exceptional Thermotropic Properties,”Chem. Commun. 23:2287-2288 (1997).
Cespedes et al., “Mouse Models in Oncogenesis and Cancer Therapy,”Clin. Transl. Oncol. 8(5):318-329 (2006).
Chatterjee et al., “Idiotypic Antibody Immunotherapy of Cancer,”Cancer Immunol. Immunother. 38:75-82 (1994).
Cheung and Paterson, “American Chemical Society—226thNational Meeting: New Drug Highlights,” IDRUGS 6(10):939-942 (2003).
Defoort et al., “Macromolecular Assemblage in the Design of a Synthetic AIDS Vaccine,”Proc. Natl. Acad. Sci. USA89:3879-3883 (1992).
Dennis, “Off by a Whisker,”Cancer News Feature442:739-741 (2006).
Dermer, “Another Anniversary for the War on Cancer,”Biotechnology12:320 (1994).
Dullenkopf et al., “Synthesis of a Structurally Defined Antigen-Immunostimulant Combination for Use in Cancer Vaccines,”Chem. Euro. J. 5(8):2432-2438 (1999).
Duralski et al., “Synthesis of Isotopically Labelled Cardiolipins,”Tetrahedron Lett. 1607-1610 (1998).
Eustache et al., “New Acyclic Analogues of Lipid A: Synthesis of 4-Phosphonoxybutyl and 3-Phosphonoxypropyl Glycosides of 2-Amino-2-Deoxy-D-Glucose,”Carbohydrate Res. 251:251-267 (1994).
Gregoriadis et al., “Liposomes as Immunological Adjuvants and Vaccine Carriers,”J. Controlled Release41(1/02):49-56 (1996).
Gura, “Systems for Identifying New Drugs are Often Faulty,”Science278:1041-1042 (1997).
Hawkins et al., “A Novel Class of Endotoxin Receptor Agonists with Simplified Structure, Toll-Like Receptor 4-Dependent Immunostimulatory Action, and Adjuvant Activity,”J. Pharmacol. Exp. Ther. 300(2):655-661 (2002).
Hawkins et al., “Inhibition of endotoxins response by synthetic TLR4 antagonists,”Curr. Topics Med. Chem. 4:1147-71 (2004).
Hoffmann et al., “Induction of Tumor Cytotoxicity in Murine Bone Marrow-Derived Macrophages by Two Synthetic Lipopeptide Analogues,”Biol. Chem. 370:575-582 (1989).
Homma et al., “Structural Requirements of Lipid A Responsible for the Functions: A Study with Chemically Synthesized Lipid A and its Analogues,”J. Biochem. 98:395-406 (1985).
Inoue and Nojima, “Immunochemical Studies of Phospholipids. I. Reactivity of Various Synthetic Cardiolipin Derivatives with Wassermann Antibody,”Chem. Phys. Lipids1(4):360-367 (1967).
Inoue and Nojima, “Immunochemical Studies of Phospholipids. II. Syntheses of Cardiolipin and its Analogues,”Chem. Pharm. Bull. 16(1):76-81 (1968).
Inoue and Nojima, “Immunochemical Studies of Phospholipids IV: The Reactivities of Antisera Against Natural Cardiolipin and Synthetic Cardiolipin Analogues-Containing Antigens,”Chem. Phys. Lipids(CPLIA4) 3(1):70-77 (1969).
Jain, “Barriers to Drug Delivery in Solid Tumors,”Scientific Americanpp. 58-65 (1994).
Jain et al., “Effect of the Structure of Phospholipid on the Kinetics of Intravesicle Scooting of Phospholipase A2,” Biochim. Biophys. Acta860(3):462-474 (1986).
Jiang and Koganty, “Synthetic Vaccines: The Role of Adjuvants in Immune Targeting,”Curr. Med. Chem. 10:1423-1439 (2003).
Kamitakahara et al., “A Lysoganglioside/poly-L-glutamic Acid Conjugate as a Picomolar Inhibitor of Influenza Hemagglutinin,”Angew. Chem. Int Ed. 37(11):1524-1528 (1998).
Lien et al., “A Novel Synthetic Acyclic Lipid A-Like Agonist Activates Cells Via the Lipopolysaccharide/Toll-Like Receptor 4 Signaling Pathway,”J. Biol. Chem. 276(3):1873-1880 (2001).
Matsuura et al., “Activity of Monosaccharide Lipid A Analogues in Human Monocytic Cells as Agonists or Antagonists of Bacterial Lipopolysaccharide,”Infect. Immun. 67(12):6286-6292 (1999).
Mitchell, “Immunotherapy as Part of Combinations for the Treatment of Cancer,”Int. Immunopharmacol. 3:1051-1059 (2003).
Przetak et al., “Novel Synthetic LPS Receptor Agonists Boost System

Affiliated with

Also associated with

Rating

Immunomodulatory compounds and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunomodulatory compounds and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulatory compounds and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2643960